Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA:688553)

Market Cap	7.06B
Revenue (ttm)	1.09B
Net Income (ttm)	253.33M
Shares Out	423.60M
EPS (ttm)	0.60
PE Ratio	27.89
Forward PE	n/a
Dividend	0.46 (2.78%)
Ex-Dividend Date	Jun 13, 2025

Volume	5,610,222
Average Volume	7,398,390
Open	16.80
Previous Close	16.65
Day's Range	16.55 - 17.09
52-Week Range	9.79 - 18.64
Beta	0.40
RSI	58.12
Earnings Date	Aug 26, 2025

About SHA:688553

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, sodium valproate concentrated solution, epirubicin hydrochloride, fulvestrant, milrinone, fluorouracil, sodium thiosulfate, zoledronic acid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 1,382
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688553

Financial Performance

In 2024, SHA:688553's revenue was 1.09 billion, an increase of 18.05% compared to the previous year's 927.08 million. Earnings were 325.39 million, an increase of 132.78%.